Credit: Getty Images As lecanemab becomes more commonly used, its effect on cardiovascular health should be analyzed. The US Food and Drug Administration’s 2023 approval of the anti-amyloid monoclonal ...

The medication lecanemab was approved by the U.S. FDA to treat Alzheimer’s disease in 2023. Like all medications, lecanemab comes with the potential for side effects, including amyloid-related imaging ...

Please provide your email address to receive an email when new articles are posted on . Patients initially received placebo then used lecanemab from 18 through 48 months. Treatment outcomes were ...

Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer’s disease (AD) enrolled in the ...

Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U.S. marketing approval. What ...

Real-World Experience: During the poster session on Monday, Dec. 1, at 3:00 PM PT and Tuesday, Dec. 2, at 5:30 PM PT, Poster 055 presents an overview of baseline characteristics and preliminary safety ...

The majority of patients with early-stage disease Alzheimer’s disease (AD) had stable or improved cognition over roughly 1 year of treatment with lecanemab (Leqembi), a real-world analysis showed. The ...

Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer's disease, their care partners and healthcare professionals, with ...

The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...

Steve Macfarlane consults for Eisai, Janssen and Eli Lilly, and participated as a researcher in the donanemab study. Eisai manufactures lecanemab, while donanemab is owned by Eli Lilly. Dementia is a ...